In Autumn 2020, DOAJ will be relaunching with a new website with updated functionality, improved search, and a simplified application form. More information is available on our blog. Our API is also changing.

Hide this message

Rheumatiod Arthritis: An Updated Overview of Latest Therapy and Drug Delivery

Journal of Pharmacopuncture. 2019;22(4):210-224 DOI 10.3831/KPI.2019.22.029

 

Journal Homepage

Journal Title: Journal of Pharmacopuncture

ISSN: 2093-6966 (Print); 2234-6856 (Online)

Publisher: Korean Pharmacopuncture Institute

LCC Subject Category: Medicine: Other systems of medicine: Miscellaneous systems and treatments | Medicine: Therapeutics. Pharmacology

Country of publisher: Korea, Republic of

Language of fulltext: English, Korean

Full-text formats available: PDF, HTML, XML

 

AUTHORS


Disha Kesharwani (Columbia Institute of Pharmacy, Raipur, Chhattisgarh, India)

Rishi Paliwal (Assistant Professor, Faculty of Pharmacy, IGNTU, Amarkantak, Madhya Pradesh, India )

Trilochan Satapathy (Columbia Institute of Pharmacy, Raipur, Chhattisgarh, India)

Swarnali Das Paul (Associate Professor, Faculty of Pharmaceutical Sciences, SSTC,SSGI,Bhilai,C.G, India)

EDITORIAL INFORMATION

Double blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 10 weeks

 

Abstract | Full Text

Rheumatoid arthritis is a severe autoimmune disorder, related to joints. It is associated with serious cartilage destruction. This causes disability and reduces the excellence of life. Numerous treatments are existed to combat this disease, however, they are not very efficient and possess severe side effects, higher doses, and frequent administration. Therefore, newer therapies are developed to overcome all these limitations. These include different monoclonal antibodies, immunoglobulins, small molecules used for immunotherapy and transgenes for gene therapy. One of the main goals of these new generation therapeutics is to address the underlying distressing biological processes by specifically targeting the causative agents with fewer systemic side effects and greater patient console. It is very fortuitous that loads of progressive investigations are going on in this field and many of them have entered into the successful clinical trial. But till date, a limited molecule has got FDA clearance and entered the market for treating this devastating disease. This review highlights the overview of conventional therapy and advancements in newer therapeutics including immunotherapy and gene therapy for rheumatoid arthritis. Further, different novel techniques for the delivery of these therapeutics of active and passive targeting are also described.